Jaundice associated with flavoxate M Sevenoaks MB BS D A Gorard MD MRCP J R Soc Med 1999; 92:589 Flavoxate hydrochloride is a smooth-muscle antispasmodic with additional analgesic and local anaesthetic properties. It is indicated for symptomatic relief of urinary tract muscle spasm in the absence of urinary obstruction. The drug is well tolerated1-3, with few side-effects other than those due to its antimuscarinic actions.
CASE HISTORY
A man aged 81 who had been taking 200mg flavoxate (Urispas 200) three times daily for three months was referred with a two-week history of painless jaundice, anorexia and fatigue. Previously he had been well. There were no risk factors for viral hepatitis and he had not been taking other drugs. He drank up to half a bottle of wine per day and had done so for many years. His only medical history of note was a prostatectomy two years earlier, with a few foci of adenocarcinoma cells in the resected tissue. On examination he was deeply jaundiced; lymphadenopathy, enlargement of the liver or spleen, and stigmata of chronic liver disease were absent.
Blood results were as follows: bilirubin 527 /imol/L, aspartate aminotransferase 923 U/L, alanine aminotransferase 1474 U/L, alkaline phosphatase 146 U/L, gamma glutamyl transferase 772 U/L, albumin 35 g/L, prothrombin time 15 s (control 13 s) and activated partial thromboplastin time 50s (control 41 s), full blood count within normal limits. An ultrasound scan of the liver and biliary tree showed nothing abnormal. Blood was IgG antibody positive but IgM antibody negative for hepatitis A, indicating previous but not recent infection. Hepatitis B surface antigen was negative, as were antibodies to cytomegalovirus and Epstein-Barr virus. Antinuclear, antismooth-muscle, anti-mitochondrial and anti-liver/kidney microsomal antibodies were all negative. Hepatitis C antibody checked six months after his jaundice was also negative.
These findings were all consistent with a hepatitic illness and excluded an obstructive jaundice. The patient was asked to stop taking flavoxate. Over a period of months his jaundice resolved and his liver function tests completely returned to normal. He returned to full health and was not rechallenged with the drug. COMMENT The manufacturers and the Committee on Safety of Medicine have received ten reports of deranged liver biochemistry associated with flavoxate (personal communications). Several of the patients had a hepatitis-like biochemical picture similar to that in our patient. In many of these cases the patients were taking other drugs and to our knowledge ours is the first report of hepatitis related to monotherapy with flavoxate. Although our patient was not rechallenged with the drug, the temporal association between the jaundice and the medication leads us to suspect that flavoxate was the cause of his jaundice.
